Help

Search Results

3 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STW 01

    The application of in vitro Toxicity Testing in 21 Century (TT21C) for next generation products

    SIMMS L.(1); TRELLES STICKEN E.(2)
    (1) Imperial Brands PLC, Bristol, U.K.; (2) Reemtsma Cigarettenfabriken GmbH (an Imperial Brands PLC Company), Hamburg, Germany
    The aim is to demonstrate the feasibility of TT21C in vitro methods as part of an overall assessment framework for next generation products (NGP). TT21C methodologies can be used to assess harm reduction potential of NGPs using human-derived...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2017, Kitzbühel, ST 62

    Overview of in vitro methods used to assess e-cigarettes based on “Toxicity Testing in 21st Century” principles

    SIMMS L.(1); STEVENSON M.(1); CZEKALA L.(1); TSCHIERSKE N.(1); WALELE T.(2)
    (1) Imperial Tobacco Ltd, Bristol, U.K.; (2) Fontem Ventures B.V. (an Imperial Brands PLC Company), Amsterdam, The Netherlands
    When the National Academies of Sciences released “Toxicity Testing in the 21st Century: A Vision and a Strategy” a new toxicological paradigm was created, focusing on the use of human cell lines and the disruption of key cellular pathways. In keeping...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2013, Seville, ST 19

    Human mouth-level transfer rate of menthol, 1.8-cineole and nicotine from Swedish pouched snus

    TROUDE V.(1); GADOIS-POMMEREUL S.(1); CLARKE A.(2); SIMMS L.(2)
    (1) SEITA, Imperial Tobacco Group, Fleury-les-Aubrais, France; (2) Imperial Tobacco Limited, Bristol, U.K.
    To facilitate the development of a transfer model which can be used to estimate human exposure to flavour and tobacco constituents, a human in vivo study involving 198 Swedish active snus users was conducted. All subjects agreed to participate in the...